68Ga-DOTA-FAPI-04 与 18F-FDG PET/CT 在胸部原发性肺外肿瘤评估中的头对头比较
前瞻性研究纳入54例受试者,比较68Ga-FAPI与18F-FDG PET/CT对胸部原发性肺外肿瘤的诊断、鉴别与分期价值。68Ga-FAPI鉴别良性与非良性病变准确率91.55%,18F-FDG鉴别恶性与非恶性病变准确率87.32%;68Ga-FAPI对转移灶检出率100%(43/43)高于18F-FDG的53.49%(23/43),并改变7.4%(4/54)受试者的治疗策略。
要点
- 68Ga-FAPI PET/CT鉴别良性与非良性病变准确率91.55%(p<0.001)。
- 68Ga-FAPI对转移灶检出率100%(43/43)高于18F-FDG的53.49%(23/43)(p<0.001)。
- 68Ga-FAPI PET/CT改变7.4%(4/54)受试者的治疗策略。
核心结论
- 68Ga-FAPI PET/CT对原发性肺外肿瘤的诊断与鉴别有价值,在评估淋巴结和远处转移方面优于18F-FDG PET/CT。
研究设计与样本
- 前瞻性研究,54例受试者均行18F-FDG与68Ga-FAPI PET/CT,依据病理分为良性、中间性和恶性组。
诊断标准与关键数值
- 18F-FDG PET/CT鉴别恶性与非恶性病变准确率87.32%(p<0.001)。
- 68Ga-FAPI PET/CT鉴别良性与非良性病变准确率91.55%(p<0.001)。
- 18F-FDG与68Ga-FAPI检测淋巴结转移准确率分别为77.22%(61/79)与87.34%(69/79)(p=0.096)。
- 68Ga-FAPI对转移灶检出率100%(43/43),18F-FDG为53.49%(23/43)(p<0.001)。
- 68Ga-FAPI在转移性淋巴结中的摄取显著高于非转移性淋巴结(p<0.001)。
临床应用与阅片要点
- 68Ga-FAPI PET/CT可用于原发性肺外肿瘤的诊断、鉴别及淋巴结与远处转移评估。
- 68Ga-FAPI PET/CT较18F-FDG PET/CT改变7.4%(4/54)受试者的治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: We conducted a prospective study using 18F-flurodeoxyglucose (18F-FDG) and 68Ga-DOTA-FAPI-04 (fibroblast-activation protein inhibitor, 68Ga-FAPI) PET/CT to diagnose, differentiate, and stage primary extrapulmonary tumors of the thorax.
METHODS: Fifty-four participants were undergoing 18F-FDG and 68Ga-FAPI PET/CT and divided into the benign, intermediate, and malignant based on pathology. The maximum standardized uptake value (SUVmax), the tumor-to-blood pool ratio, and tumor-to-liver ratio were compared for primary tumors, lymph nodes, and metastases between the two modalities by two independent samples t tests. One-way ANOVA was used to compare the uptake of 18F-FDG or 68Ga-FAPI among the three groups.
RESULTS: Fifty-four participants were confirmed to have 71 primary lesions, 56 metastatic lymph nodes, and 43 metastatic lesions. 18F-FDG PET/CT could both effectively distinguish malignant lesions from non-malignant lesions, accuracies of 87.32% (p < 0.001). 68Ga-FAPI PET/CT effectively differentiated benign lesions from the non-benign, accuracy being 91.55% (p < 0.001). The accuracies of 18F-FDG and 68Ga-FAPI for detecting lymph node metastasis were 77.22% (61/79) and 87.34% (69/79) (p = 0.096). The uptake of 68Ga-FAPI in metastatic lymph nodes was significantly higher than that of the nonmetastatic (p < 0.001). The detection rate of 68Ga-FAPI PET/CT for metastatic lesions was significantly higher than that of 18F-FDG, 100% (43/43) vs. 53.49% (23/43) (p < 0.001). Compared with 18F-FDG PET/CT, 68Ga-FAPI PET/CT changed the treatment strategy of 7.4% (4/54) participants.
CONCLUSION: 68Ga-FAPI PET/CT is valuable in the diagnosis and differentiation of primary extrapulmonary tumors and superior to 18F-FDG PET/CT for evaluating lymph node and distant metastasis.
CLINICAL RELEVANCE STATEMENT: The application of 68Ga-FAPI PET/CT in primary extrapulmonary chest tumors is valuable, which is reflected in diagnosis, differentiation and exploration of lymph node metastasis and distant metastasis.
KEY POINTS: • 68Ga-FAPI PET/CT is valuable in the diagnosis, differentiation, and staging of primary extrapulmonary tumors. • 68Ga-FAPI PET/CT is superior to 18 F-FDG PET/CT for evaluating lymph node and distant metastasis.
引用
- Zhang A, Meng X, Yao Y, et al. Head to head comparison of 68Ga-DOTA-FAPI-04 vs 18F-FDG PET/CT in the evaluation of primary extrapulmonary tumors in the chest. Eur Radiol. 2023. PMID: 37668694. doi:10.1007/s00330-023-10130-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。